PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

被引：38

作者：

Banerjee, Susana ^{[2
]}

Kaye, Stan ^{[1
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Div Clin Studies, Inst Canc Res, Drug Dev Unit, Sutton SM2 5PT, Surrey, England

[2] Royal Marsden NHS Fdn Trust, Gynaecol Unit, Sutton SM2 5PT, Surrey, England

来源：

CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 06期

关键词：

PARP inhibitors; Ovarian cancer; BRCA; Olaparib; Endometrial; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; MUTANT-CELLS; TUMOR; MUTATIONS; CARCINOMA; FEATURES; DELETION; REPAIR;

D O I：

10.1007/s11912-011-0193-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.

引用

页码：442 / 449

页数：8

共 50 条

[21] PARP inhibition — moving beyond BRCA-mutated disease
David Killock
Nature Reviews Clinical Oncology, 2017, 14 : 71 - 71
[22] Combination treatment of PARP and SRC inhibitors in BRCA2 mutated prostate cancer
Khan, Nabeela
Chakraborty, Goutam
Nandakumar, Subhiksha
Mazzu, Ying Z.
Atiq, Mohammad
Yoshikawa, Yuki
Lee, Gwo-Shu Mary
Kantoff, Philip
CANCER RESEARCH, 2019, 79 (13)
[23] Survival outcomes in BRCA pathogenetic mutated, variant of unknown significance, and wild type ovarian cancer patients treated with PARP inhibitors
Musacchio, L.
Marchetti, C.
Boccia, S. M.
Cassani, C.
Ventriglia, J.
Salutari, V.
Camarda, F.
Ghizzoni, V.
Giudice, E.
Carbone, M. V.
Pignata, S.
Scambia, G.
Lorusso, D.
ANNALS OF ONCOLOGY, 2022, 33 : S396 - S396
[24] Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren R. Hodgson
Brian A. Dougherty
Zhongwu Lai
Anitra Fielding
Lynda Grinsted
Stuart Spencer
Mark J. O’Connor
Tony W. Ho
Jane D. Robertson
Jerry S. Lanchbury
Kirsten M. Timms
Alexander Gutin
Maria Orr
Helen Jones
Blake Gilks
Chris Womack
Charlie Gourley
Jonathan Ledermann
J. Carl Barrett
British Journal of Cancer, 2018, 119 : 1401 - 1409
[25] Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Hodgson, D. R.
Dougherty, B.
Lai, Z.
Grinsted, L.
Spencer, S.
O'Connor, M. J.
Ho, T. W.
Robertson, J. D.
Lanchbury, J.
Timms, K.
Gutin, A.
Orr, M.
Jones, H.
Gilks, B.
Womack, C.
Sun, J.
Yelensky, R.
Gourley, C.
Ledermann, J.
Barrett, J. C.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S90 - S90
[26] Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Hodgson, Darren R.
Dougherty, Brian A.
Lai, Zhongwu
Fielding, Anitra
Grinsted, Lynda
Spencer, Stuart
O'Connor, Mark J.
Ho, Tony W.
Robertson, Jane D.
Lanchbury, Jerry S.
Timms, Kirsten M.
Gutin, Alexander
Orr, Maria
Jones, Helen
Gilks, Blake
Womack, Chris
Gourley, Charlie
Ledermann, Jonathan
Barrett, J. Carl
BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 1401 - 1409
[27] PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Frizzell, Kristine M.
Kraus, W. Lee
BREAST CANCER RESEARCH, 2009, 11 (06):
[28] PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Menezes, Maria Clara Saad
Raheem, Farah
Mina, Lida
Ernst, Brenda
Batalini, Felipe
CANCERS, 2022, 14 (17)
[29] PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Kristine M Frizzell
W Lee Kraus
Breast Cancer Research, 11
[30] Poly ADP ribose polymerase (PARP) for the treatment of BRCA-mutated advanced ovarian cancer
Yunokawa, Mayu
ANNALS OF ONCOLOGY, 2019, 30 : 47 - 47

← 1 2 3 4 5 →